LL-37.

Quick Overview.

LL-37 is the only naturally occurring antimicrobial peptide (AMP) in the human cathelicidin family. It is produced by various cells in the body, including neutrophils (white blood cells) and epithelial cells, in response to infection or injury.[1]

Unlike traditional antibiotics that target specific metabolic pathways in bacteria, LL-37 acts as a physical weapon. Because it has a positive electrical charge, it is magnetically attracted to the negative charge on the outer membranes of bacteria and fungi. When it makes contact, it physically punches holes in their cell walls, causing them to rupture and die.[2] Furthermore, it acts as a signaling molecule, calling other immune cells to the site of infection to help clear the debris.

• Primary Use Case: Chronic, antibiotic-resistant infections (Lyme disease, Candida, SIBO), wound healing, and biofilm disruption.
• Mechanism: Directly disrupts the lipid membranes of pathogens and modulates the local immune response to accelerate tissue repair.[1]
• Who it is for: Individuals battling stubborn, chronic infections that have stopped responding to traditional antibiotics, or those with hard-to-heal wounds.
• Who it is NOT for: Individuals with severe autoimmune diseases (like psoriasis or lupus), as LL-37 can act as an autoantigen and trigger flare-ups.

The Protocol & Usage Guide.

confidence_tier: well-established

LL-37 is a powerful compound. Because it directly destroys pathogens, it can cause a severe "die-off" reaction (Herxheimer reaction) as toxins are released into the bloodstream. It must be dosed carefully.

Standard Dosing

Note: LL-37 is dosed very low compared to other peptides to avoid cytotoxicity (damage to healthy cells).

Cycle Length

• Standard Cycle: 4 to 6 weeks. Prolonged continuous use is not recommended due to the risk of cytotoxicity and potential autoimmune triggering.[6]
• Discontinuation: Can be stopped abruptly.

Reconstitution Math

• Vial Size: 2 mg (2,000 mcg)
• Bacteriostatic Water Added: 2 mL
• Concentration: 1,000 mcg per mL
• To draw 100 mcg: Pull to the 10-unit mark (0.1 mL) on a U-100 insulin syringe.

Nutritional Support & Recommended Supplements.

confidence_tier: well-established

Safety, Interactions & Side Effect Management.

confidence_tier: well-established

Side Effect Profile

Contraindications

• Absolute: Individuals with severe autoimmune diseases (e.g., psoriasis, lupus, rheumatoid arthritis). LL-37 is known to act as an autoantigen in these conditions, potentially triggering severe flare-ups.
• Relative: Pregnant or breastfeeding women.

Drug Interactions

• Antibiotics: LL-37 is highly synergistic with traditional antibiotics. It is often used to restore the efficacy of antibiotics against resistant strains by breaking down the protective biofilms that bacteria hide behind.[3]

Common Stacks & Combinations.

confidence_tier: community

Body Composition & Training Guide.

confidence_tier: community

LL-37 has no direct application for muscle growth, fat loss, or athletic performance. Its use in athletes is strictly limited to treating stubborn infections or severe wounds that are preventing them from training.

Storage, Handling & Accessibility.

confidence_tier: well-established

• Unreconstituted (Lyophilized Powder): Store in the freezer (-20°C) for up to 24 months.
• Reconstituted (Liquid): Must be stored in the refrigerator (2-8°C). Good for 30 days.
• WADA Status: Not explicitly banned, as it is not an anabolic agent or hormone secretagogue.[8]

Bloodwork Monitoring Guide.

confidence_tier: emerging

If using LL-37 to treat a chronic infection, monitor:

• Vitamin D (25-OH): Ensure levels are optimal (50-80 ng/mL) to support natural LL-37 production.
• Inflammatory Markers: CRP and ESR to track the resolution of the infection.
• Liver/Kidney Function: CMP to ensure the organs are handling the toxic load of the die-off reaction appropriately.

Comparison to Similar Compounds.

confidence_tier: well-established

Deep Dive (For Advanced Researchers).

confidence_tier: well-established

Mechanism of Action

LL-37 is a 37-amino acid cationic, amphipathic alpha-helical peptide. It is cleaved from its precursor protein, hCAP18, by proteinase 3 in neutrophils.[1]

1. Direct Antimicrobial Activity: Due to its cationic (positive) charge, LL-37 binds electrostatically to the anionic (negative) lipopolysaccharides (LPS) on Gram-negative bacteria and teichoic acids on Gram-positive bacteria. It inserts itself into the lipid bilayer, forming transmembrane pores that cause leakage of intracellular contents and cell death.[2]
2. Biofilm Disruption: One of LL-37's most valuable clinical properties is its ability to inhibit the formation of bacterial biofilms and degrade existing ones at sub-inhibitory concentrations. It does this by decreasing bacterial attachment and influencing quorum sensing (how bacteria communicate).[3]
3. Immunomodulation: LL-37 neutralizes LPS (endotoxin), suppressing the massive inflammatory response that usually accompanies bacterial death. It also acts as a chemoattractant, recruiting neutrophils, monocytes, and T-cells to the site of infection.[1]

Clinical Trial Summary

• Wound Healing: A Phase IIb double-blind, randomized, placebo-controlled clinical trial demonstrated that topical application of LL-37 significantly enhanced the healing rate of hard-to-heal venous leg ulcers compared to placebo, with an excellent safety profile.[4]
• Biofilm Eradication: Extensive in vitro studies have proven LL-37's efficacy in eradicating biofilms formed by notorious pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, which are highly resistant to standard antibiotics.[5]

Frequently Asked Questions (FAQ).

confidence_tier: community

Q: What is a Herxheimer reaction? A: When LL-37 kills a large number of bacteria or fungi rapidly, the dying pathogens burst open and release endotoxins into your bloodstream. Your body reacts to these toxins with systemic inflammation, causing fatigue, brain fog, joint pain, and mild fever. It means the peptide is working, but you should lower the dose to make the symptoms manageable.

Q: Can I take LL-37 if I have an autoimmune disease? A: It is highly discouraged. LL-37 is overexpressed in the skin of psoriasis patients and is known to act as an autoantigen, triggering the immune system to attack healthy tissue. If you have an autoimmune condition, consider KPV or BPC-157 instead.

Q: Does it work against viruses? A: While its primary mechanism is antibacterial and antifungal, LL-37 has demonstrated antiviral activity against certain enveloped viruses (like Influenza and HIV) by disrupting their viral envelopes. However, Thymosin Alpha-1 is generally preferred for chronic viral infections.

International Regulatory Status.

confidence_tier: well-established

Decision Tree.

confidence_tier: community

[Goal: Treat a Stubborn Infection or Wound?]
  |
  +-- Do you have a severe autoimmune disease (e.g., Psoriasis, Lupus)?
        |
        +-- (Yes) -> STOP: LL-37 can trigger severe flare-ups. Consider KPV instead.
        |
        +-- (No) -> Is the infection hiding behind a biofilm (e.g., Chronic Lyme, SIBO)?
              |
              +-- (Yes) -> Use LL-37 (100-150mcg daily). Start at 50mcg to assess die-off reaction.
              |
              +-- (No, it is a viral infection) -> Consider Thymosin Alpha-1 instead.

Schema.org Data.

{
  "@context": "https://schema.org",
  "@type": "MedicalEntity",
  "name": "LL-37",
  "alternateName": ["Cathelicidin Antimicrobial Peptide", "hCAP18 fragment"],
  "description": "A naturally occurring human antimicrobial peptide that directly destroys bacterial and fungal membranes, disrupts biofilms, and accelerates wound healing.",
  "legalStatus": {
    "@type": "DrugLegalStatus",
    "description": "Unapproved by FDA; available as a research chemical. Not prohibited by WADA."
  }
}

What we cited.